
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| THIOGUANINE | Waylis Therapeutics | N-012429 RX | 1982-01-01 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
|---|---|---|
| tabloid | New Drug Application | 2025-01-08 |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 4 | 22 | 33 | 6 | 4 | 64 |
| Leukemia | D007938 | — | C95 | 3 | 20 | 33 | 5 | 4 | 62 |
| Lymphoid leukemia | D007945 | — | C91 | 2 | 13 | 14 | 4 | 2 | 33 |
| Lymphoma | D008223 | — | C85.9 | 1 | 8 | 9 | 1 | — | 16 |
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | 1 | — | 1 | 1 | — | 3 |
| Crohn disease | D003424 | EFO_0000384 | K50 | — | — | 1 | 1 | — | 2 |
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | — | — | — | 1 | — | 1 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | — | — | 1 | — | 1 |
| Pancreatitis | D010195 | EFO_0000278 | K85 | — | — | — | 1 | — | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myeloid leukemia acute | D015470 | — | C92.0 | — | 1 | 10 | — | 1 | 12 |
| Myeloid leukemia | D007951 | — | C92 | — | 1 | 9 | — | 1 | 11 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | 5 | 5 | — | — | 10 |
| Burkitt lymphoma | D002051 | — | C83.7 | 1 | 2 | 6 | — | — | 9 |
| Precursor t-cell lymphoblastic leukemia-lymphoma | D054218 | — | — | — | 3 | 4 | — | — | 6 |
| Myelodysplastic syndromes | D009190 | — | D46 | — | — | 6 | — | — | 6 |
| Biphenotypic leukemia acute | D015456 | — | C95.0 | — | 2 | 2 | — | 1 | 5 |
| Down syndrome | D004314 | EFO_0001064 | Q90 | — | — | 4 | — | — | 4 |
| Syndrome | D013577 | — | — | — | — | 4 | — | — | 4 |
| Acute disease | D000208 | — | — | — | 1 | 1 | — | 1 | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Urologic neoplasms | D014571 | — | C64-C68 | — | 1 | — | — | — | 1 |
| Carcinoma | D002277 | — | C80.0 | — | 1 | — | — | — | 1 |
| Urinary bladder neoplasms | D001749 | — | C67 | — | 1 | — | — | — | 1 |
| Transitional cell carcinoma | D002295 | — | — | — | 1 | — | — | — | 1 |
| Glioblastoma | D005909 | EFO_0000515 | — | — | 1 | — | — | — | 1 |
| Glioma | D005910 | EFO_0000520 | — | — | 1 | — | — | — | 1 |
| Thrombocytopenia | D013921 | HP_0001873 | D69.6 | — | 1 | — | — | — | 1 |
| Histiocytosis | D015614 | HP_0100727 | — | — | 1 | — | — | — | 1 |
| Langerhans-cell histiocytosis | D006646 | — | C96.6 | — | 1 | — | — | — | 1 |
| Hodgkin disease | D006689 | — | C81 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | — | — | — | — | 1 | 1 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 1 | 1 |
| Malaria | D008288 | EFO_0001068 | B54 | — | — | — | — | 1 | 1 |
| Asymptomatic diseases | D058070 | — | — | — | — | — | — | 1 | 1 |
| Drug common name | Thioguanine |
| INN | tioguanine |
| Description | Tioguanine is a 2-aminopurine that is the 6-thiono derivative of 2-amino-1,9-dihydro-6H-purine. Incorporates into DNA and inhibits synthesis. Used in the treatment of leukaemia. It has a role as an antineoplastic agent, an antimetabolite and an anticoronaviral agent. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | Nc1nc2[nH]cnc2c(=S)[nH]1 |
| PDB | — |
| CAS-ID | 154-42-7 |
| RxCUI | 1546005 |
| ChEMBL ID | CHEMBL727 |
| ChEBI ID | 9555 |
| PubChem CID | 2723601 |
| DrugBank | DB00352 |
| UNII ID | WIX31ZPX66 (ChemIDplus, GSRS) |






